Black Diamond Therapeutics, Inc. (BDTX) vs Insight Molecular Diagnostics Inc. (IMDX)
A side-by-side comparison of Black Diamond Therapeutics, Inc. and Insight Molecular Diagnostics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
BDTX
Black Diamond Therapeutics, Inc.
$1.88HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
IMDX
Insight Molecular Diagnostics Inc.
$3.50HealthcareDelayed quote: Oct 6, 2026, 1:00 PM EDT
Total return — BDTX vs IMDX
growth of $100 · dividends reinvested · last 7yBDTX -95.1% (-35.0%/yr)IMDX -93.3% (-32.0%/yr)IMDX compounded faster over this window
BDTX IMDX
BDTX vs IMDX: by the numbers
- •IMDX is the larger company ($113M vs $107M market cap).
- •BDTX is profitable (31.95% net margin) while IMDX runs a net loss (-2955.63%).
Metrics side by side
Valuation
| Metric | BDTX | IMDX |
|---|---|---|
| P/S ratio | N/A | 67.67 |
| P/B ratio | 1.12 | N/A |
Profitability
| Metric | BDTX | IMDX |
|---|---|---|
| Gross margin | 99.54% | 11.17% |
| Operating margin | 28.39% | -754.08% |
| Net margin | 31.95% | -2955.63% |
| ROE | -44.29% | N/A |
| ROIC | -47.54% | -223.06% |
Growth (annualized)
| Metric | BDTX | IMDX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 27.24% |
| Total return CAGR (5Y) | -24.47% | -44.39% |
Frequently asked
- Is BDTX or IMDX more profitable?
- BDTX runs the higher net margin — BDTX at 31.95% versus IMDX at -2955.63%.
- How have BDTX and IMDX total returns compared?
- Over the past 5 years, BDTX delivered -24.47% and IMDX delivered -44.39% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Black Diamond Therapeutics ROEInsight Molecular Diagnostics ROEBlack Diamond Therapeutics operating marginInsight Molecular Diagnostics operating marginBlack Diamond Therapeutics revenue growthInsight Molecular Diagnostics revenue growthBlack Diamond Therapeutics free cash flowInsight Molecular Diagnostics free cash flow
Black Diamond Therapeutics & Insight Molecular Diagnostics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.